MedTrace Logo

Single Dose, Dose-Ranging Study of 11-β Methyl Nortestosterone Dodecylcarbonate (11β-MNTDC) in Healthy Men

NCT02754687 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2025-10-31

No results posted yet for this study

Summary

The long term objective is to develop a new male hormone 11-β Methyl Nortestosterone Dodecylcarbonate (11β-MNTDC) as a male hormonal contraceptive.

Conditions

  • Healthy Men
  • Male Contraception

Interventions

DRUG

Placebo

Placebo with capsules that look like the 11β-MNTDC capsules but with no active ingredients

DRUG

11βmethyl nortestosterone dodecylcarbonate

Escalating doses of 100, 200, 400, and 800 mg 11β-MNTDC

Sponsors & Collaborators

  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

    collaborator NIH

  • University of Washington

    collaborator OTHER

  • Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

    collaborator OTHER

  • Premier Research

    lead OTHER

Principal Investigators

  • Christina Wang, MD · Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

  • Stephanie Page, MD, PhD · University of Washington

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-07-14
Primary Completion
2017-01-23
Completion
2017-06-05

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02754687 on ClinicalTrials.gov